Jonathan Snedeker, a high school senior in Boulder, has been researching novel therapies for acute myeloid leukemia, a cancer with a particularly poor prognosis, at the University of Colorado Anschutz Medical Campus. He focused on targeting AML’s key escape pathways, the proteins cancers are reliant on to survive the intrinsic increases in DNA damage, increases in replication rate, and the other hallmarks of cancer. His work was published as an abstract in Blood, and he presented the results at the American Society of Hematology annual meeting.